Skip to main content
Menu

Accelerating CAR-T Cell Therapy

Scalable solutions, smarter editing, and faster delivery for your next breakthrough in cell therapy

Developing CAR-T therapies requires precision, speed, and scale. Revvity empowers researchers, biopharma innovators, and CDMO/CRO partners with an integrated portfolio of technologies and assays - from high-fidelity genome editing to optimized vector delivery and functional testing.

Whether you're advancing autologous or allogeneic CAR-T programs, our platforms help de-risk development and accelerate time to clinic.

What we offer:

  • Modular gene editing with Pin-point™ base editing platform
  • High-efficiency lentiviral transduction with LentiBOOST™ technology and QA/QC evaluation with microfluidic based CE – LabChip™ system
  • GMP-grade, cell culture and ancillary reagents for ex vivo cell bioprocessing and downstream applications
  • T cell functional assays and detection platforms
  • CRISPR screens
  • Cell counters
  • High-content imaging
Accelerating CAR-T Cell Therapy

For research use only. Not for use in diagnostic procedures.

Pin-point™ Reagents & Platform: Pin-point™ base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals. The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.

LentiBOOST™ Pharma-Grade: For research use only. Not for use in diagnostic procedures.

Revvity AI Assistant Beta